|
|
 Previous Article | Table of Contents | Next Article 
A possible correlation between the type of bcr-abl hybrid messenger RNA and
platelet count in Philadelphia-positive chronic myelogenous leukemia [see
comments]
K Inokuchi, T Inoue, A Tojo, M Futaki, K Miyake, T Yamada, Y Tanabe, I Ohki, K Dan and K Ozawa
Third Department of Internal Medicine, Nippon Medical School, Japan.
The Philadelphia (Ph1) chromosome, in which the hybrid bcr-abl gene is
formed, is thought to be the initial event in chronic myelogenous leukemia
(CML). The position of the breakpoint within the breakpoint cluster region
(bcr) on Ph1 chromosome and the splicing pattern determine the species of
the fused bcr-abl messenger RNA (mRNA). We tried to detect the two types of
fused mRNAs in 57 chronic-phase cases of Ph1-positive CML using the
polymerase chain reaction procedure (RT- PCR). The bcr exon 2/abl exon 2
fused mRNA (b2-a2) was detected in 17 patients, the bcr exon 3/abl exon 2
fused mRNA (b3-a2) was detected in 34 patients, and both types of mRNA were
detected in six patients. The platelet counts of patients who expressed
b3-a2 mRNA or both types were significantly higher than those of patients
who expressed only b2-a2 (841.5 v 373.5 x 10(9)/L; P less than .015),
although there was no significant difference in the white blood cell counts
or hemoglobin. This finding suggests a possibility that the type of bcr-abl
mRNA may affect the thrombopoietic activity in CML.
Volume 78,
Issue 12,
pp. 3125-3127,
12/15/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. S. Huettner, S. Koschmieder, H. Iwasaki, J. Iwasaki-Arai, H. S. Radomska, K. Akashi, and D. G. Tenen
Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome
Blood,
November 1, 2003;
102(9):
3363 - 3370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Inokuchi, K. Dan, M. Takatori, H. Takahuji, N. Uchida, M. Inami, K. Miyake, H. Honda, H. Hirai, and T. Shimada
Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis
Blood,
July 1, 2003;
102(1):
320 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Honda, H. Oda, T. Suzuki, T. Takahashi, O. N. Witte, K. Ozawa, T. Ishikawa, Y. Yazaki, and H. Hirai
Development of Acute Lymphoblastic Leukemia and Myeloproliferative Disorder in Transgenic Mice Expressing p210bcr/abl: A Novel Transgenic Model for Human Ph1-Positive Leukemias
Blood,
March 15, 1998;
91(6):
2067 - 2075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
